Lilly’s CYRAMZA meets primary endpoint in phase 3 RELAY trial

This article was originally published here

The Phase 3 global, randomized, double-blind trial is evaluating CYRAMZA in combination with erlotinib, compared to placebo in combination with erlotinib, as a first-line treatment in patients with

The post Lilly’s CYRAMZA meets primary endpoint in phase 3 RELAY trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply